In this issue:
The addition of daratumumab to a lenalidomide and dexamethasone regimen in RRMM
Benefit of the addition of daratumumab to a bortezomib and dexamethasone regimen in RRMM
Elotuzumab plus lenalidomide and dexamethasone in RRMM
Daratumumab resistance may be overcome in MM patients by ex vivo– expanded autologous NK cells
Lower glomerular filtration rate predicts increased hepatic toxicity in myeloma patients treated with high-dose melphalan
Allogeneic transplantation of MM patients may allow long-term survival
Lenalidomide and dexamethasone in patients with RRMM and impaired renal function
Changes in end-of-life care among patients with myeloma
Ixazomib-melphalan-prednisone induction followed by ixazomib maintenance in transplant-ineligible NDMM
A novel bromodomain and extraterminal domain inhibitor induces vulnerabilities in myeloma cells
Please login below to download this issue (PDF)